白细胞介素4诱导蛋白1（IL4I1）抑制剂作为癌症的潜在治疗方法。
Inhibitors of Interleukin 4 Induced Protein 1 (IL4I1) as Potential Treatment for Cancer.
作者信息
Abdel-Magid Ahmed F
机构信息
Therachem Research Medilab, LLC, 100 Jade Park, Chelsea, Alabama 35043, United States.
出版信息
ACS Med Chem Lett. 2023 Jan 17;14(2):127-128. doi: 10.1021/acsmedchemlett.2c00525. eCollection 2023 Feb 9.
Abstract
The invention in this patent application relates to piperazine-2,3-dione derivatives represented generally by formula 1. These compounds show activities as selective interleukin 4 induced protein 1 (IL4I1) inhibitors and may potentially be useful in preventing and treating IL4Il-related diseases, such as endometrial, ovarian, and triple negative breast cancers.
摘要
本专利申请中的发明涉及一般由式1表示的哌嗪-2,3-二酮衍生物。这些化合物表现出作为选择性白细胞介素4诱导蛋白1（IL4I1）抑制剂的活性，并且可能潜在地用于预防和治疗与IL4I1相关的疾病，如子宫内膜癌、卵巢癌和三阴性乳腺癌。
相似文献
1
Inhibitors of Interleukin 4 Induced Protein 1 (IL4I1) as Potential Treatment for Cancer.
ACS Med Chem Lett. 2023 Jan 17;14(2):127-128. doi: 10.1021/acsmedchemlett.2c00525. eCollection 2023 Feb 9.
2
Inhibitors of Son of Sevenless Isoform 1 (SOS1) as a Potential Treatment for RAS Mutant Cancers.
ACS Med Chem Lett. 2023 Dec 13;15(1):9-11. doi: 10.1021/acsmedchemlett.3c00521. eCollection 2024 Jan 11.
3
Inhibitors of the Cyclic GMP-AMP Synthase (cGAS) as Potential Treatment for Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett. 2024 Aug 22;15(9):1424-1426. doi: 10.1021/acsmedchemlett.4c00392. eCollection 2024 Sep 12.
4
Positive Allosteric Modulators of alpha7 Nicotinic Acetylcholine Receptor for the Treatment of Several Central Nervous System Diseases.
ACS Med Chem Lett. 2023 Dec 13;15(1):6-8. doi: 10.1021/acsmedchemlett.3c00520. eCollection 2024 Jan 11.
5
Plasma Kallikrein Inhibitors as Potential Treatment for Diabetic Macular Edema, Retinal Vein Occlusion, Hereditary Angioedema and Other Related Diseases.
ACS Med Chem Lett. 2023 Jan 17;14(2):129-130. doi: 10.1021/acsmedchemlett.2c00526. eCollection 2023 Feb 9.
6
Targeting the Inhibition of B-Cell Lymphoma 2 Protein for the Treatment of Cancer.
ACS Med Chem Lett. 2023 Sep 18;14(10):1320-1322. doi: 10.1021/acsmedchemlett.3c00379. eCollection 2023 Oct 12.
7
Amino Acid-Metabolizing Enzymes in Advanced High-Grade Serous Ovarian Cancer Patients: Value of Ascites as Biomarker Source and Role for IL4I1 and IDO1.
Cancers (Basel). 2023 Jan 31;15(3):893. doi: 10.3390/cancers15030893.
8
[The role of IL4I1 in immunoregulation: An update].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2021 Jan;37(1):79-83.
9
Somatostatin Receptor Subtype 4 Agonists for Potential Treatment of Alzheimer's Disease and Other Central Nervous System Disorders.
ACS Med Chem Lett. 2024 May 6;15(6):766-768. doi: 10.1021/acsmedchemlett.4c00185. eCollection 2024 Jun 13.
10
IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression.
Cell. 2020 Sep 3;182(5):1252-1270.e34. doi: 10.1016/j.cell.2020.07.038. Epub 2020 Aug 19.
引用本文的文献
1
The Complex World of Kynurenic Acid: Reflections on Biological Issues and Therapeutic Strategy.
Int J Mol Sci. 2024 Aug 20;25(16):9040. doi: 10.3390/ijms25169040.
2
Distinct functions of wild-type and R273H mutant Δ133p53α differentially regulate glioblastoma aggressiveness and therapy-induced senescence.
Cell Death Dis. 2024 Jun 27;15(6):454. doi: 10.1038/s41419-024-06769-5.
3
Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma.
Nat Commun. 2024 Mar 8;15(1):2113. doi: 10.1038/s41467-024-46220-z.
4
Distinct functions of wild-type and R273H mutant Δ133p53α differentially regulate glioblastoma aggressiveness and therapy-induced senescence.
Res Sq. 2023 Nov 2:rs.3.rs-3370608. doi: 10.21203/rs.3.rs-3370608/v1.
本文引用的文献
1
Interleukin 4-Induced Gene 1 as an Emerging Regulator of B-Cell Biology and its Role in Cutaneous Melanoma.
Crit Rev Immunol. 2019;39(1):39-57. doi: 10.1615/CritRevImmunol.2019030020.
2
The IL4I1 Enzyme: A New Player in the Immunosuppressive Tumor Microenvironment.
Cells. 2019 Jul 20;8(7):757. doi: 10.3390/cells8070757.
3
IL4I1: an inhibitor of the CD8⁺ antitumor T-cell response in vivo.
Eur J Immunol. 2011 Jun;41(6):1629-38. doi: 10.1002/eji.201041119. Epub 2011 May 13.
Zotero 插件